
What if the biggest breakthroughs in biotech don’t come from more capital—but from building better systems for innovation? In this episode, I sit down with Errik Anderson, biotech entrepreneur and founder behind multiple billion-dollar companies, to discuss how building infrastructure, not just drugs, is reshaping the future of healthcare. Errik explains why most biotech companies fail the same way, how reducing the cost and time of experimentation unlocks more innovation, and why staying private longer enables better long-term decision making. We also explore compounding in biotech, the limits of scaling creativity, and how conviction, mission, and talent ultimately determine which companies change the world.
AI Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

E359: What Charlie Munger Taught Me About Venture Capital

E358: The Woman Behind the World's Top GP Brands | Jen Prosek

E357: CalSTRS CIO: Where Do You Invest $390 Billion Today?

E356: Why Co-Investments Are Taking Over Private Equity
Free AI-powered recaps of How I Invest with David Weisburd and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.